Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.25 USD | -2.34% | +3.27% | +45.65% |
Financials (USD)
Sales 2024 * | 147M | Sales 2025 * | 165M | Capitalization | 147M |
---|---|---|---|---|---|
Net income 2024 * | -146M | Net income 2025 * | -182M | EV / Sales 2024 * | 1.51 x |
Net Debt 2024 * | 74M | Net cash position 2025 * | - | EV / Sales 2025 * | 0.89 x |
P/E ratio 2024 * |
-1.04
x | P/E ratio 2025 * |
-1.22
x | Employees | 325 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.01% |
Latest transcript on Karyopharm Therapeutics Inc.
1 day | -7.25% | ||
1 week | -4.48% | ||
Current month | -15.23% | ||
1 month | -12.93% | ||
3 months | +76.82% | ||
6 months | +8.94% | ||
Current year | +47.98% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Paulson
CEO | Chief Executive Officer | 56 | 20-02-25 |
Mike Mason
DFI | Director of Finance/CFO | 49 | 19-02-24 |
Amama Sadiq
CTO | Chief Tech/Sci/R&D Officer | - | 23-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Garen Bohlin
BRD | Director/Board Member | 76 | 13-10-02 |
Barry Greene
BRD | Director/Board Member | 60 | 12-12-31 |
Director/Board Member | 59 | 13-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 1.26 | -1.57% | 602 539 |
24-04-18 | 1.28 | -7.25% | 1,306,165 |
24-04-17 | 1.38 | +25.45% | 3,175,612 |
24-04-16 | 1.1 | -4.76% | 1,171,346 |
24-04-15 | 1.155 | -5.33% | 810,682 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.98% | 147M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.19% | 21.66B | |
-18.35% | 20.77B | |
-7.77% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- KPTI Stock